TH.TO - Theratechnologies Inc.
| Previous Close | 4.0100 |
| Open | 4.1800 |
| Bid | 4.0100 x 0 |
| Ask | 4.0300 x 0 |
| Day's Range | 4.0000 - 4.1800 |
| 52 Week Range | 3.7000 - 9.7400 |
| Volume | 168,621 |
| Avg. Volume | 78,576 |
| Market Cap | 311M |
| Beta (3Y Monthly) | 0.80 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0890 |
| Earnings Date | Oct 8, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 7.29 |
- GlobeNewswire
Theratechnologies’ CFO to Attend Piper Jaffray 31st Annual Healthcare Conference in New York City
Theratechnologies Inc. (Theratechnologies) (TH.TO) is pleased to announce that Philippe Dubuc, Senior Vice President and Chief Financial Officer will attend the 31st Annual Healthcare Conference starting at 12:30 p.m. on December 3rd, 2019 at the Lotte New York Palace in New York City. Mr. Dubuc will hold several meetings with representatives from various investment firms to discuss the latest developments announced by the Company including the approval of Trogarzo® in Europe by the European Commission and the publication of clinical trial results in the Lancet HIV on the effects of tesamorelin on Non-alcoholic Fatty Liver Disease (NAFLD) in people living with HIV.
- GlobeNewswire
Theratechnologies Starts Commercialization of New EGRIFTA SVᵀᴹ in the United States
Theratechnologies Inc. (Theratechnologies) (TH.TO) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, is pleased to announce that EGRIFTA SVᵀᴹ (2mg/vial) is now commercially available in the United States.
- GlobeNewswire
Theratechnologies’ CFO to Attend Stifel Healthcare Conference in New York City
Theratechnologies Inc. (Theratechnologies) (TH.TO), a commercial-stage biopharmaceutical company, is pleased to announce that Philippe Dubuc, Senior Vice President and Chief Financial Officer, will attend the Stifel Healthcare Conference which will be held in New York City on November 19th, 2019. Mr. Dubuc will hold several meetings with representatives from various investment firms to discuss the latest developments announced by the Company including the approval of Trogarzo® in Europe by the European Commission and the publication of clinical trial results in the Lancet HIV on the effects of tesamorelin on Non-alcoholic Fatty Liver Disease (NAFLD) in people living with HIV.
- GlobeNewswire
Trogarzo® Remains Effective Close to a Decade After Treatment Initiation
Theratechnologies Inc. (Theratechnologies) (TH.TO) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, is pleased to announce that data presented at the 17th European AIDS Conference, currently being held in Basel, Switzerland, demonstrate that Trogarzo® (ibalizumab-uiyk) remains safe and effective in patients having been on treatment for almost a decade. Cohort 1 included 12 patients rolled over from an Investigator-sponsored Investigational New Drug (PI-IND) protocol upon completion of TMB-202, a Phase 2 clinical trial of Trogarzo®. Cohort 1 also included 27 patients who had participated in the Phase 3 clinical trial TMB-301.
- GlobeNewswire
Theratechnologies Provides Details About R&D Day Webcast
Theratechnologies (TH.TO) is a commercial-stage pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including those living with HIV. Further information about Theratechnologies is available on the Company's website at www.theratech.com, on SEDAR at www.sedar.com and on EDGAR at www.sec.gov.
- Simply Wall St.
Does Theratechnologies Inc.'s (TSE:TH) CEO Salary Compare Well With Others?
Luc Tanguay has been the CEO of Theratechnologies Inc. (TSE:TH) since 2012. First, this article will compare CEO...
- GlobeNewswire
REMINDER - Tesamorelin Study Results on NAFLD Published in Lancet HIV
Theratechnologies Inc. (Theratechnologies) (TH.TO) (NASDAQ:THTX) is pleased to announce that results from a recent trial conducted at the Massachusetts General Hospital and the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health on the effects of tesamorelin on Non-alcoholic Fatty Liver Disease (NAFLD) in HIV were published today in the Lancet HIV. NAFLD is a substantial cause of liver-related morbidity in people living with HIV and is a precursor of Non-alcoholic steatohepatitis (NASH). The randomized, double-blind, multicenter trial assessed the effect of tesamorelin on liver fat and histology in people living with HIV with NAFLD.
- GlobeNewswire
Tesamorelin Study Results on NAFLD Published in Lancet HIV
Theratechnologies Inc. (Theratechnologies) (TH.TO) (NASDAQ:THTX) is pleased to announce that results from a recent trial conducted at the Massachusetts General Hospital and the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health on the effects of tesamorelin on Non-alcoholic Fatty Liver Disease (NAFLD) in HIV were published today in the Lancet HIV. NAFLD is a substantial cause of liver-related morbidity in people living with HIV and is a precursor of Non-alcoholic steatohepatitis (NASH). The randomized, double-blind, multicenter trial assessed the effect of tesamorelin on liver fat and histology in people living with HIV with NAFLD.
- Thomson Reuters StreetEvents
Edited Transcript of TH.TO earnings conference call or presentation 8-Oct-19 12:30pm GMT
Q3 2019 Theratechnologies Inc Earnings Call
- GlobeNewswire
Canadian Commercial-Stage Biopharmaceutical Company Theratechnologies Announces NASDAQ Listing
“Theratechnologies’ NASDAQ listing is yet another step forward for our Company with growing sales from two commercialized products and a strong pipeline. Over the last five years, we have reached significant milestones and our progress continues.
- GlobeNewswire
Theratechnologies Announces Financial Results for the Third Quarter of 2019
Theratechnologies Inc. (Theratechnologies) (TH.TO) today announced its financial results for the third quarter ended August 31, 2019. The coming days and weeks will be no exception with the expected listing of our common shares on NASDAQ and the anticipated commercial launch of EGRIFTA SVTM in the United States,” said Luc Tanguay, President and CEO, Theratechnologies Inc.
- GlobeNewswire
1.7 Million Dollars Grant Towards Development of Theratechnologies’ Targeted Oncology
Theratechnologies Inc. (Theratechnologies) (TH.TO) is pleased to announce that the Canadian Cancer Society and the Government of Quebec, through the Consortium Québécois sur la découverte du médicament (CQDM), will contribute to a grant totaling 1.7 million dollars to l’Université du Québec à Montréal (UQAM) as part of the overall investment made by Theratechnologies towards the development of its targeted oncology platform. The funds have been earmarked for work conducted by Dr Borhane Annabi at the Molecular Oncology Laboratory of the UQAM. Dr Annabi and his team will focus their efforts on the development of the targeted oncology platform in triple-negative breast cancer.
- GlobeNewswire
New 48-Week Data Presented at IDWeek Show Trogarzo® Remains Safe and Effective
Theratechnologies Inc. (Theratechnologies) (TH.TO) is pleased to announce that new 48-week data from the TMB-311 extension study confirm that Trogarzo® provides durable viral suppression and a safety profile consistent with the 24-week pivotal Phase III study. Patients had a viral load 1,000 copies/mL, resistance to at least 1 antiretroviral from three different classes and full viral sensitivity to at least 1 antiretroviral. In Cohort 2 patients, viral load reduction at week 24 and week 48 was comparable.
- GlobeNewswire
Theratechnologies to Announce Financial Results for Third Quarter 2019
MONTREAL, Oct. 01, 2019 -- Theratechnologies Inc. (TSX: TH) (Theratechnologies) announced today that it will issue its financial results for the third quarter ended August 31,.
- GlobeNewswire
Theratechnologies to Present at Cantor Fitzgerald Global Healthcare Conference in New York City
Theratechnologies Inc. (Theratechnologies) (TH.TO) is pleased to announce that Philippe Dubuc, Senior Vice President and Chief Financial Officer will make a presentation at the 2019 Cantor Fitzgerald Global Healthcare Conference on October 2, 2019 in New York City. The presentation will start at 8:55 a.m. “The presentation will be a great opportunity to give a full update on the many projects we have going at Theratechnologies.
- GlobeNewswire
European Commission Approves Trogarzo®
Theratechnologies Inc. (Theratechnologies) (TH.TO) is pleased to announce that Trogarzo® (ibalizumab) was approved today by the European Commission. “The approval of Trogarzo® by the European Commission represents a historical milestone for Theratechnologies as it becomes our first product ever approved in that territory. Already, we are recording sales in Europe through early access programs, which shows that there is already a high level of interest for our unique HIV treatment,” said Luc Tanguay, President and CEO, Theratechnologies Inc.
- GlobeNewswire
Theratechnologies Included in the First TSX30 Ranking
Theratechnologies Inc. (Theratechnologies) (TH.TO) is pleased to announce that it ranked 21st on the first TSX30 ranking of top performers on the Toronto Stock Exchange. Common shares of Theratechnologies were trading at $2.71 on June 30, 2016 and at $7.06 on June 30, 2019, representing an increase of 161% over that period.
- GlobeNewswire
Theratechnologies Reaches Agreement With AIDS Drug Assistance Program (ADAP) for New EGRIFTA SV™
Theratechnologies Inc. (TH.TO) is pleased to announce that an agreement has been reached with the AIDS Drug Assistance Program Crisis Task Force for EGRIFTA SVTM (tesamorelin for injection), which will commercially launch in the United States very shortly. The agreement will help to facilitate access to low income, underinsured and uninsured Americans living with HIV in all 50 states and territories of the United States. EGRIFTA SVTM is a growth hormone-releasing factor.
- GlobeNewswire
Theratechnologies Ranks Among Canada’s 500 Fastest Growing Companies
Theratechnologies Inc. (Theratechnologies) (TH.TO) is pleased to announce that it has been recognized as 137th fastest growing Canadian companies over the last five years according to the 2019 Growth 500 ranking released today by Canadian Business and Maclean’s. This is just the beginning as we pursue our goal of becoming a significant player among commercial-stage biopharmaceutical companies,” said Luc Tanguay, President and Chief Executive Officers, Theratechnologies Inc. “Given the continued growth of our two commercialized products, the development of tesamorelin for NASH in people living with HIV and of the promising sortilin receptor specific oncology platform, we have given ourselves the tools to remain among the fastest growing Canadian companies,” added Luc Tanguay.
- Simply Wall St.
Have Insiders Been Selling Theratechnologies Inc. (TSE:TH) Shares This Year?
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
- GlobeNewswire
Theratechnologies Files Application to List on NASDAQ
“We believe that being listed on NASDAQ will help to foster interest from more potential investors and financial analysts, and that it should result in increased liquidity for investors. In connection with its application to list on NASDAQ, Theratechnologies will file a Form 40-F Registration Statement with the United States Securities and Exchange Commission.
- GlobeNewswire
Theratechnologies Regains Control Over Distribution Rights to EGRIFTA® Worldwide
Theratechnologies Inc. (Theratechnologies) (TH.TO) is pleased to announce that it has regained complete control over distribution rights of EGRIFTA® worldwide, following the termination of agreements with commercial partners in various territories outside of the United States and Canada. “Given our announced objective to develop tesamorelin for NASH in people living with HIV and expansion into Europe, we have concluded that regaining rights to EGRIFTA® in territories outside of the United States and Canada is the best strategic position for us. The treatment of NASH in patients living with HIV represents a potential opportunity for EGRIFTA® many times the size of lipodystrophy.
- GlobeNewswire
Jean-Denis Talon Retires From Theratechnologies’ Board of Directors
Theratechnologies Inc. (Theratechnologies) (TH.TO) today announced that Mr. Jean-Denis Talon has decided to retire from the board of directors of Theratechnologies. “I feel honored and privileged to have served for so many years on the board of directors of Theratechnologies. The Company is now recognized as a long-standing success story of the biotech sector in Quebec and abroad.
- GlobeNewswire
Theratechnologies’ CFO to Attend 39ᵗʰ Annual Growth Conference Held by Canaccord Genuity in Boston
Theratechnologies Inc. (Theratechnologies) (TH.TO) is pleased to announce that Philippe Dubuc, Senior Vice President and Chief Financial Officer, will attend the 39th Annual Growth Conference held by Canaccord Genuity in Boston, Massachusetts, from August 6 to August 8, 2019. Theratechnologies (TH.TO) is a specialty pharmaceutical company addressing unmet medical needs by bringing to market specialized therapies for people with orphan medical conditions, including those living with HIV. Further information about Theratechnologies is available on the Company's website at www.theratech.com and on SEDAR at www.sedar.com.
